Evidence map›Paper›PMID 28976179›Full record

ArticleACS infectious diseases2017

Trio Act of Boronolectin with Antibiotic-Metal Complexed Macromolecules toward Broad-Spectrum Antimicrobial Efficacy.

Peng Yang, Marpe Bam, Parasmani Pageni, Tianyu Zhu, Yung Pin Chen, Mitzi Nagarkatti, Alan W Decho, Chuanbing Tang

Abstract read
In one paragraph

Article in ACS infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Peng YangDepartment of Chemistry and Biochemistry, University of South Carolina , 631 Sumter Street, Columbia, South Carolina 29208, United States.
Marpe BamDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina , 6311 Garners Ferry Road, Columbia, South Carolina 29209, United States.
Parasmani PageniDepartment of Chemistry and Biochemistry, University of South Carolina , 631 Sumter Street, Columbia, South Carolina 29208, United States.
Tianyu ZhuDepartment of Chemistry and Biochemistry, University of South Carolina , 631 Sumter Street, Columbia, South Carolina 29208, United States.
Yung Pin ChenDepartment of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina , 921 Assembly Street, Columbia, South Carolina 29208, United States.
Mitzi NagarkattiDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina , 6311 Garners Ferry Road, Columbia, South Carolina 29209, United States.
Alan W DechoDepartment of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina , 921 Assembly Street, Columbia, South Carolina 29208, United States.
Chuanbing TangDepartment of Chemistry and Biochemistry, University of South Carolina , 631 Sumter Street, Columbia, South Carolina 29208, United States.ORCID 0000-0002-0242-8241
University of South Carolina · USUniversity of South Carolina Sumter · US

Funding

Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
Use of Resveratrol to treat experimental multiple sclerosisP01AT003961 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2007 to 2018
$14.2M
Metallopolymer and Antibiotic Bioconjugates against Multidrug Resistant BacteriaR01AI120987 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI TANG, CHUANBING · 2016 to 2019
$1.4M
NCCIH NIH HHS P01 AT003961NIAID NIH HHS R01 AI120987NIGMS NIH HHS P20 GM103641
6 · The paper itself

Abstract

Bacterial infections, particularly by Gram-negative pathogens, have become a serious threat to global healthcare due to the diminishing effectiveness of existing antibiotics. We report a nontraditional therapy to combine three components in one macromolecular system, in which boronic acid adheres to peptidoglycan or lipopolysaccharide via boron-polyol based boronolectin chemistry, cationic metal polymer frameworks interact with negatively charged cell membranes, and β-lactam antibiotics are reinstated with enhanced vitality to attack bacteria via evading the detrimental enzyme-catalyzed hydrolysis. These macromolecular systems exhibited high efficacy in combating pathogenic bacteria, especially Gram-negative strains, due to synergistic effects of multicomponents on interactions with bacterial cells. In vitro and in vivo cytotoxicity and hemolysis evaluation indicated that these multifunctional copolymers did not induce cell death by apoptosis, as well as did not alter the phenotypes of immune cells and did not show observable toxic effect on red blood cells.

Indexed as

AnimalsAnti-Bacterial AgentsApoptosisBacteriaBoron CompoundsCells, CulturedFemaleMacromolecular SubstancesMetalsMiceMice, Inbred C57BLMicrobial ViabilityMolecular StructureMonosaccharidesPolymersSpleenAnti-Bacterial AgentsBoron CompoundsboronolectinMacromolecular SubstancesMetalsMonosaccharidesPolymersantibioticsantimicrobialboronic acidboronolectincationic macromoleculescobaltocenium

Identifiers

PMID28976179
PMCPMC5681415
OpenAlexW2761144693

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.